QBD10903
Fmoc-N-amido-dPEG®36-acid
>95% (HPLC)
Synonym(s):
Fmoc-N-amido-PEG36-acid, Fmoc-NH-PEG36-acid, Fmoc-PEG-acid, Fmoc-PEG1500-acid, Fmoc-PEG36-acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Assay
>95% (HPLC)
form
solid or viscous liquid
reaction suitability
reaction type: Pegylations
polymer architecture
shape: linear
functionality: heterobifunctional
shipped in
ambient
storage temp.
−20°C
Features and Benefits
Fmoc-N-amido-dPEG36-acid is a monodisperse PEG product that is useful for peptide synthesis. The 112-atom dPEG spacer allows the introduction of a long, hydrophilic spacer onto either end of a peptide chain or between two peptide chains. The flexible dPEG spacer conjugates to peptides using conventional peptide synthesis chemistry. Peptide PEGylation imparts water solubility to hydrophobic peptide chains. Also, PEGylated peptides have expanded hydrodynamic volumes, which can reduce or eliminate renal clearance, and are protected from proteolysis. The combination of decreased renal clearance and protection from proteolysis contributes to longer in vivo circulation times for PEGylated (as compared to non-PEGylated) peptides. Additionally, PEGylation diminishes a peptide′s antigenicity. Fmoc-N-amido-dPEG36-acid is the monodisperse PEG equivalent of polymeric PEG1500. This product is part of the Fmoc-N-amido-dPEGn-acid (n=2, 3, 4, 5, 6, 8, 12, 24, 36) product series.
Legal Information
Products Protected under U.S. Patent #s 7,888,536 & 8,637,711 and European Patent #s 1,594,440 & 2,750,681
dPEG is a registered trademark of Quanta BioDesign
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Biomacromolecules, 18(8), 2509-2520 (2017-06-27)
Here, we report novel lipo-oligoaminoamide nanoformulations for targeted intracellular protein delivery. Formulations are generated by first bioreversibly conjugating a sequence-defined amphiphilic lipo-oligomer 728 to the cargo protein via disulfide bonds, followed by formulation of the formed 728-SS-protein conjugate with different
ACS nano, 7(4), 2935-2947 (2013-02-21)
PEGylated liposomes are attractive pharmaceutical nanocarriers; however, literature reports of ligand-targeted nanoparticles have not consistently shown successful results. Here, we employed a multifaceted synthetic strategy to prepare peptide-targeted liposomal nanoparticles with high purity, reproducibility, and precisely controlled stoichiometry of functionalities
Bioconjugate chemistry, 27(7), 1762-1769 (2016-07-01)
As tumors grow, vasculature is often deficient or malformed, resulting in many localized areas of hypoxia. Cells located in these hypoxic regions exhibit an altered gene expression pattern that can significantly alter resistance to conventional anticancer treatments such as ionizing
Biomacromolecules, 15(5), 1543-1559 (2014-04-12)
The remarkable diversity of the self-assembly behavior of PEG-peptides is reviewed, including self-assemblies formed by PEG-peptides with β-sheet and α-helical (coiled-coil) peptide sequences. The modes of self-assembly in solution and in the solid state are discussed. Additionally, applications in bionanotechnology
ACS nano, 7(9), 8115-8127 (2013-09-06)
Ligand-targeted nanoparticles are emerging drug delivery vehicles for cancer therapy. Here, we demonstrate that the cellular uptake of peptide-targeted liposomes and micelles can be significantly enhanced by increasing the hydrophilicity of the targeting peptide sequence while simultaneously optimizing the EG
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service